Becton Dickinson and Co

Becton, Dickinson and Company, commonly known as BD, is a United States-based global medical-technology company. It develops, manufactures, and distributes medical devices, diagnostic systems, laboratory equipment, and related software and services. Although the supplied industry classification identified the business as generic pharmaceuticals, that classification does not match the company’s principal identity: BD is primarily a medical-device, diagnostics, and life-sciences technology group rather than a generic-drug manufacturer. The company was established in 1897 by Maxwell W. Becton and Fairleigh S. Dickinson. Its early business was associated with medical and surgical supplies, and it gradually built a broad portfolio around injection, specimen collection, laboratory, and hospital-use products. Over time, BD became particularly associated with syringes, needles, blood-collection systems, safety-engineered devices, and diagnostic technologies. Its products are used by hospitals, physicians, pharmacies, clinical laboratories, pharmaceutical manufacturers, research institutions, and patients. BD’s business spans several connected areas. Its medication-management activities include infusion pumps, infusion sets, drug-delivery components, prefillable systems, and technologies intended to support safer preparation and administration of medicines. The company also supplies vascular-access and injection products, sharps-safety systems, surgical and urology devices, and products used in oncology and other procedural specialties. In diagnostics and laboratory science, BD provides molecular and microbiology systems, specimen-collection products, flow-cytometry platforms, cell-analysis tools, reagents, and other research technologies. A major phase of expansion came through acquisitions. BD acquired CareFusion in 2015, adding substantial medication-management, infusion, respiratory-care, and patient-monitoring capabilities. In 2017 it completed the acquisition of C. R. Bard, strengthening its presence in vascular, urology, oncology, surgery, and other specialized medical-device markets. These transactions helped transform BD from a company strongly identified with injection and laboratory products into a diversified medical-technology platform. The BD brand is generally positioned around clinical reliability, infection prevention, medication safety, laboratory productivity, and support for healthcare workflows. Its customers often purchase products through institutional procurement channels, making regulatory compliance, clinical evidence, supply continuity, interoperability, and service support important parts of the brand proposition. BD also markets selected products directly or indirectly to consumers, including some diabetes-care and home-use injection products, although the company’s primary commercial base remains professional healthcare and life-sciences users. BD operates internationally, with manufacturing and commercial activities across North America, Latin America, Europe, Asia, and other regions. Reported manufacturing locations include the United States, Canada, Brazil, the Dominican Republic, France, Germany, Hungary, India, Japan, Mexico, and Bosnia and Herzegovina, among others. The company remains headquartered in Franklin Lakes, New Jersey, and is led by Thomas E. Polen, who serves as chairman, president, and chief executive officer. Its current identity is that of a large, diversified healthcare-technology company serving clinical care, diagnostics, research, pharmaceutical production, and medication delivery.

Becton, Dickinson and Company was founded in 1897 by Maxwell W. Becton and Fairleigh S. Dickinson. The business developed within the expanding market for medical and surgical supplies and eventually became closely associated with injection products, needles, syringes, specimen collection, and laboratory equipment. Its long-term development was shaped by the increasing standardization of hospital care, the growth of clinical laboratories, and demand for safer ways to administer and collect medicines and biological samples. During the twentieth century, BD broadened beyond basic instruments and supplies. The company developed and commercialized products used in parenteral drug delivery, blood collection, infection prevention, and laboratory diagnostics. Its portfolio came to serve multiple customer groups, including hospitals, physicians, laboratories, pharmaceutical companies, researchers, and public-health organizations. This diversification helped BD participate in both routine clinical care and more specialized life-sciences workflows. The company’s modern expansion has relied partly on acquisitions. In 2015, BD acquired CareFusion in a transaction valued at approximately $12 billion. CareFusion brought businesses in medication management, infusion delivery, respiratory care, and related hospital technologies. The acquisition significantly increased BD’s presence in hospital workflow and medication-safety markets. In 2017, BD announced and completed its acquisition of C. R. Bard in a cash-and-stock deal valued at approximately $24 billion. Bard added established businesses in vascular care, oncology, surgery, urology, and other procedural fields. The transaction expanded BD’s specialty-device capabilities and increased the scale of the combined company in high-growth areas of medical technology. BD now operates as a diversified healthcare-technology group. Its activities include injection and blood-collection products, vascular access, infusion and medication-management systems, prefillable drug-delivery components, surgical and urological devices, molecular diagnostics, microbiology, flow cytometry, cell analysis, and laboratory research tools. Manufacturing and commercial operations extend across numerous countries, including the United States, Canada, Brazil, the Dominican Republic, France, Germany, Hungary, India, Japan, Mexico, and Bosnia and Herzegovina. The BD brand is not best understood as a pharmaceutical brand. Its principal role is to provide the devices, systems, consumables, diagnostics, and laboratory technologies that support the delivery of healthcare and the development and manufacture of medicines. The company’s current strategy and communications emphasize patient safety, infection prevention, efficient clinical workflows, medication administration, diagnostic accuracy, and innovation in life-sciences research. Thomas E. Polen became chairman, president, and chief executive officer in 2021. BD remains headquartered in Franklin Lakes, New Jersey, and continues to operate as a publicly traded global medical-technology company.

1. 2021Thomas E. Polen becomes chairman and CEO

   Thomas E. Polen assumed the roles of chairman, president, and chief executive officer.

   Source
2. 2017C. R. Bard acquisition announced

   BD announced an approximately $24 billion cash-and-stock acquisition of C. R. Bard, adding major oncology, surgery, vascular, and urology businesses.

   Source
3. 2015CareFusion acquisition

   BD acquired CareFusion, expanding into infusion, medication management, respiratory care, and hospital technologies.
4. 1897Company founded

   Maxwell W. Becton and Fairleigh S. Dickinson established Becton, Dickinson and Company in the United States.

A global healthcare-technology partner focused on safer medication delivery, injection and vascular access, infection prevention, diagnostics, laboratory science, and specialized procedural care.

• BD AlarisInfusion and medication management

  BD Alaris is a family of infusion and medication-management technologies used in clinical settings to help deliver fluids, medicines, and nutrition. The offering is associated with infusion pumps, administration sets, and related systems intended to support hospital workflows and medication-safety practices.

• BD VacutainerBlood collection

  BD Vacutainer is a blood-collection product family used by healthcare professionals and laboratories. It includes collection tubes and related devices designed to standardize specimen collection, transport, and preparation for diagnostic testing.

• BD COR SystemMolecular diagnostics

  The BD COR System is a laboratory automation and molecular-diagnostics platform designed to support testing workflows. BD’s communications present it as a system intended to integrate instruments, assays, and workflow processes for clinical laboratories.

• BD Aptra UreteroscopeUrology

  The BD Aptra Ureteroscope is a urology device used in endoscopic procedures involving the urinary tract. BD promoted the product through physician-focused educational and testimonial video content in the United States.

• BD FACSLyricFlow cytometry and cell analysis

  BD FACSLyric is part of BD’s flow-cytometry portfolio. Such systems enable laboratories to analyze cells and other particles using fluorescence and related measurements, supporting clinical testing, biomedical research, and immunology applications.

• BD PlastipakSyringes and drug delivery

  BD Plastipak is a syringe family used for medical injection and medication administration. The products are supplied in formats for healthcare, pharmaceutical, and other professional applications and form part of BD’s longstanding injection-technology business.

• 2023BD COR System Value Proposition

  United States

  An internet video campaign communicated the clinical and workflow value of the BD COR System to a professional healthcare audience.

  Source
• 2023BD Aptra Ureteroscope physician testimonial

  United States

  BD used a physician-led video featuring Dr. Stoller to discuss the BD Aptra Ureteroscope and its relevance to urological practice.

  Source

• 2017Acquire C. R. BardM&A

  BD identified oncology, surgery, vascular care, and urology as areas where the combined company could expand its medical-device presence.

  What changed. BD agreed to acquire C. R. Bard in a cash-and-stock transaction valued at approximately $24 billion.

  Aftermath. Bard became part of BD, broadening the company’s specialty-device portfolio and geographic reach.

  Transaction value. Approximately $24 billion (2017 announcement)

  Source
• 2015Acquire CareFusionM&A

  BD sought to broaden its medical-technology portfolio and increase its presence in medication management and hospital care.

  What changed. BD completed the acquisition of CareFusion in a transaction valued at approximately $12 billion.

  Aftermath. The transaction added infusion, respiratory-care, and medication-management businesses to BD’s operations.

• 2023BD promotes the clinical value of the COR System

  BD used an internet video to communicate the value proposition of its COR System, a platform associated with interventional and procedural care.

  Campaign
  Source
• 2023BD presents the BD Aptra ureteroscope through physician-led video

  A physician testimonial video highlighted the BD Aptra ureteroscope for a United States clinical audience.

  CampaignProduct launch
  Source
• 2017BD agrees to acquire C. R. Bard for approximately $24 billion

  BD announced a cash-and-stock transaction for C. R. Bard. The combination expanded BD’s presence in oncology, surgery, vascular care, and urology, with Bard shareholders expected to own about 15% of the combined company.

  M&A
  Source

1. BD company overview and media profile
2. BD executive profile
3. BD media and campaign listings
4. CNBC report on BD’s acquisition of C. R. Bard